Subcutaneous versus intravenous trastuzumab for HER2-positive breast cancer: a global systematic review and meta-analysis with a cost-minimization analysis from the Chinese healthcare system perspective. [PDF]
Front PharmacolZeng Z +9 more
europepmc +1 more source
Delayed Cardiac Dysfunction During Prolonged Use of Trastuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer. [PDF]
Breast Cancer (Dove Med Press)Chen X +8 more
europepmc +1 more source
Case Report: HER2-positive vulvar Paget disease achieving long-term control with trastuzumab-based systemic therapy plus radiotherapy. [PDF]
Front Med (Lausanne)Xie X, Chen Q, Zhang J, Peng X.
europepmc +1 more source
Optimizing adjuvant endocrine therapy in premenopausal patients with HER2-positive, hormone receptor-positive breast cancer. [PDF]
BreastValenza C, Partridge AH, Regan MM.
europepmc +1 more source
Breast Cancer Brain Metastases: Current Understanding and Future Directions. [PDF]
Curr Oncol RepAlabdulrahman M +12 more
europepmc +1 more source
Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach. [PDF]
Clin Cancer ResAdesoye T +12 more
europepmc +1 more source
Serum HER2 extracellular domain as a predictive biomarker for trastuzumab deruxtecan treatment response in HER2-positive gastric cancer: a real-world study. [PDF]
Ther Adv GastroenterolNarita Y +10 more
europepmc +1 more source
Comparing infectious risk of Trastuzumab-deruxtecan to Trastuzumab-emtansine in patients with breast cancer. [PDF]
Breast Cancer Res TreatGayfield S +9 more
europepmc +1 more source